Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
NCT ID NCT04935684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves survival without GvHD or relapse one year later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fecal microbiota transplantation (FMT) given as an enema
- What this could lead to
- If it works, this could offer a simple way to prevent serious complications after stem cell transplants, improving survival and quality of life for blood cancer patients.
- What could go wrong
- This is a mid-stage trial with 150 people, so results are not yet proven. FMT carries a small risk of infection or side effects, and the benefit may not be seen in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Département d'hématologie CAC Rouen
NOT_YET_RECRUITINGRouen, France
-
Hématologie clinique CHU Besançon
NOT_YET_RECRUITINGBesançon, France
-
Hématologie clinique Institut de Cancérologie de la Loire
NOT_YET_RECRUITINGSaint-Etienne, France
-
Hématologie clinique et thérapie cellulaire Hôpital Haut-Lévèque
NOT_YET_RECRUITINGPessac, France
-
IUC T - Oncopôle
NOT_YET_RECRUITINGToulouse, France
-
Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-Ferrand
RECRUITINGClermont-Ferrand, France
-
Service Maladies du sang CHU Angers
NOT_YET_RECRUITINGAngers, France
-
Service d'Hématologie Adultes Hôpital Necker
RECRUITINGParis, France
-
Service d'Hématologie Centre Hospitalier Lyon Sud
NOT_YET_RECRUITINGLyon, France
-
Service d'Hématologie Clinique CHU Nantes
NOT_YET_RECRUITINGNantes, France
-
Service d'Hématologie Clinique et Thérapie Cellulaire CHU Amiens Picardie - Site Sud
NOT_YET_RECRUITINGAmiens, France
-
Service d'Hématologie clinique Hôpital Pitié-Salpêtrière
NOT_YET_RECRUITINGParis, France
-
Service d'Hématologie et de Médecine interne Hôpital Brabois CHRU Nancy
NOT_YET_RECRUITINGNancy, France
-
Service d'hématologie clinique, département de greffe de moelle CHU Nice
NOT_YET_RECRUITINGNice, France
-
Service d'hématologie greffe Hôpital St Louis
NOT_YET_RECRUITINGParis, France
-
Service d'hématologie greffe Hôpital St Louis
NOT_YET_RECRUITINGPoitiers, France
-
Service de thérapie Cellulaire et d'Hématologie Clinique Adulte CHU Estaing - Clermont-Ferrand
NOT_YET_RECRUITINGClermont-Ferrand, France
-
Service de thérapie cellulaire et l'hématologie clinique adulte CHU Limoges
NOT_YET_RECRUITINGLimoges, France
-
Service des Maladies du sang Hôpital HURIEZ, CHRU de Lille
NOT_YET_RECRUITINGLille, France
-
Service hématologie CHU Grenoble
NOT_YET_RECRUITINGGrenoble, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors